Results 1 to 10 of about 289,605 (341)

Modification of PLAC8 by UFM1 affects tumorous proliferation and immune response by impacting PD-L1 levels in triple-negative breast cancer

Journal for ImmunoTherapy of Cancer, 2022
Background Triple-negative breast cancer is characterized by a poor prognosis and lack of targeted treatments, and thus, new targeting markers and therapeutic strategies are urgently needed.
Cong Chen, Linbo Wang, Xun Zhang, Ling Xu, Misha Mao, Yongxia Chen, Jingjing Yang, Yifan Cheng, Feiyang Ji, Jichun Zhou, Zhaoqing Li, Siwei Ju, Jiahang Zhang   +12 more
doaj   +1 more source

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

New England Journal of Medicine, 2021
Copyright © 2021 Massachusetts Medical Society. BACKGROUND Patients with metastatic triple-negative breast cancer have a poor prognosis. Sacituzumab govitecan is an antibody–drug conjugate composed of an antibody targeting the human trophoblast cell ...
A. Bardia, S. Hurvitz, S. Tolaney, D. Loirat, K. Punie, Mafalda Oliveira, A. Brufsky, S. Sardesai, K. Kalinsky, A. Zelnak, R. Weaver, T. Traina, F. Dalenc, P. Aftimos, F. Lynce, S. Diab, J. Cortés, J. O’Shaughnessy, V. Diéras, C. Ferrario, P. Schmid, L. Carey, L. Gianni, M. Piccart, S. Loibl, D. Goldenberg, Q. Hong, M. Olivo, L. Itri, H. Rugo   +29 more
semanticscholar   +1 more source

Clinical Implications of iNOS Levels in Triple-Negative Breast Cancer Responding to Neoadjuvant Chemotherapy. [PDF]

PLoS ONE, 2015
Triple-negative breast cancer is a high-risk breast cancer with poor survival rate. To date, there is a lack of targeted therapy for this type of cancer. One unique phenomenon is that inflammatory breast cancer is frequently triple negative.
Zining Jin, Wenqian Wang, Nan Jiang, Lei Zhang, Yiming Li, Xiaoyin Xu, Shouliang Cai, Liang Wei, Xuhong Liu, Guanglei Chen, Yizhen Zhou, Cheng Liu, Zhan Li, Feng Jin, Bo Chen   +14 more
doaj   +1 more source

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.

New England Journal of Medicine, 2022
BACKGROUND The addition of pembrolizumab to neoadjuvant chemotherapy led to a significantly higher percentage of patients with early triple-negative breast cancer having a pathological complete response (defined as no invasive cancer in the breast and ...
P. Schmid, J. Cortés, R. Dent, L. Pusztai, H. McArthur, S. Kümmel, J. Bergh, C. Denkert, Yeon-Hee Park, R. Hui, N. Harbeck, M. Takahashi, M. Untch, P. Fasching, F. Cardoso, J. Andersen, D. Patt, M. Danso, M. Ferreira, M. Mouret-Reynier, S. Im, J. Ahn, M. Gion, S. Baron-Hay, J. Boileau, Yu Ding, K. Tryfonidis, G. Aktan, V. Karantza, J. O’Shaughnessy   +29 more
semanticscholar   +1 more source

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.

New England Journal of Medicine, 2022
BACKGROUND In an interim analysis of this phase 3 trial, the addition of pembrolizumab to chemotherapy resulted in longer progression-free survival than chemotherapy alone among patients with advanced triple-negative breast cancer whose tumors expressed ...
J. Cortés, H. Rugo, D. Cescon, S. Im, M. Yusof, C. Gallardo, O. Lipatov, C. Barrios, J. Peréz-García, H. Iwata, N. Masuda, M. Torregroza Otero, E. Gokmen, S. Loi, Zifang Guo, Xuan Zhou, V. Karantza, W. Pan, P. Schmid   +18 more
semanticscholar   +1 more source

Pembrolizumab for Early Triple-Negative Breast Cancer.

New England Journal of Medicine, 2020
BACKGROUND Previous trials showed promising antitumor activity and an acceptable safety profile associated with pembrolizumab in patients with early triple-negative breast cancer.
P. Schmid, J. Cortés, L. Pusztai, H. McArthur, S. Kümmel, J. Bergh, C. Denkert, Yeon-Hee Park, R. Hui, N. Harbeck, M. Takahashi, T. Foukakis, P. Fasching, F. Cardoso, M. Untch, L. Jia, V. Karantza, J. Zhao, G. Aktan, R. Dent, J. O’Shaughnessy   +20 more
semanticscholar   +1 more source

Metabolic Reprogramming in Triple-Negative Breast Cancer

Frontiers in Oncology, 2020
Metabolic reprogramming is an emerging hallmark of cancer cells, in which cancer cells exhibit distinct metabolic phenotypes to fuel their proliferation and progression.
Xiangyu Sun, Mozhi Wang, Mengshen Wang, Xueting Yu, Jingyi Guo, Tie Sun, Xinyan Li, Litong Yao, Haoran Dong, Yingying Xu   +9 more
doaj   +1 more source

HJURP regulates cell proliferation and chemo-resistance via YAP1/NDRG1 transcriptional axis in triple-negative breast cancer

Cell Death and Disease, 2022
Triple-negative breast cancer is still a difficult point in clinical treatment at present, and a deep study of its pathogenesis has great clinical value. Therefore, our research mainly focuses on exploring the progression of triple-negative breast cancer
Misha Mao, Yunlu Jia, Yongxia Chen, Jingjing Yang, Ling Xu, Xun Zhang, Jichun Zhou, Zhaoqing Li, Cong Chen, Siwei Ju, Linbo Wang   +10 more
doaj   +1 more source

Triple-negative breast cancer molecular subtyping and treatment progress

Breast Cancer Research, 2020
Triple-negative breast cancer (TNBC), a specific subtype of breast cancer that does not express estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER-2), has clinical features that include high invasiveness,
Li Yin, Jiang-jie Duan, X. Bian, Shi-cang Yu   +3 more
semanticscholar   +1 more source

MiR-133 Targets YES1 and Inhibits the Growth of Triple-Negative Breast Cancer Cells

Technology in Cancer Research & Treatment, 2020
Triple-negative breast cancer shows worse outcome compared with other subtypes of breast cancer. The discovery of dysregulated microRNAs and their roles in the progression of triple-negative breast cancer provide novel strategies for the treatment of ...
Guochen Zhang MD, Junlan Wang BS, Ruilin Zheng MD, Beibei Song BS, Li Huang PhD, Yujiang Liu MD, Yating Hao MD, Xiangdong Bai PhD   +7 more
doaj   +1 more source